CC
ABBV icon

Centiva Capital’s AbbVie ABBV Stock Holding History

Centiva Capital’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-5,000
Closed -$889K – 1488
2024
Q4 		$889K Sell
5,000
-1,300
-21% -$239K 0.02% 567
2024
Q3 		$1.24M Buy
6,300
+1,300
+26% +$243K 0.02% 723
2024
Q2 		$858K Buy
+5,000
New +$828K 0.01% 852
2024
Q1 		– Sell
-7,200
Closed -$1.12M – 1713
2023
Q4 		$1.12M Sell
7,200
-17,000
-70% -$2.48M 0.03% 567
2023
Q3 		$3.61M Buy
24,200
+17,000
+236% +$2.5M 0.08% 226
2023
Q2 		$970K Buy
7,200
+4,200
+140% +$616K 0.02% 575
2023
Q1 		$478K Sell
3,000
-1,500
-33% -$229K 0.01% 861
2022
Q4 		$727K Sell
4,500
-800
-15% -$123K 0.02% 664
2022
Q3 		$711K Sell
5,300
-21,600
-80% -$3.1M 0.01% 754
2022
Q2 		$4.12M Sell
26,900
-15,700
-37% -$2.4M 0.1% 184
2022
Q1 		$6.91M Sell
42,600
-53,900
-56% -$7.83M 0.13% 109
2021
Q4 		$13.1M Buy
96,500
+92,850
+2,544% +$11M 0.27% 67
2021
Q3 		$394K Buy
+3,650
New +$417K 0.02% 703
2021
Q2 		– Sell
-2,100
Closed -$227K – 1352
2021
Q1 		$227K Sell
2,100
-8,100
-79% -$866K 0.01% 925
2020
Q4 		$1.09M Sell
10,200
-10,200
-50% -$980K 0.04% 250
2020
Q3 		$1.79M Sell
20,400
-21,200
-51% -$2M 0.12% 126
2020
Q2 		$4.08M Sell
41,600
-20,900
-33% -$1.84M 0.25% 57
2020
Q1 		$4.75M Sell
62,500
-11,500
-16% -$980K 0.21% 72
2019
Q4 		$6.55M Buy
74,000
+39,100
+112% +$3.25M 0.32% 69
2019
Q3 		$2.64M Sell
34,900
-21,900
-39% -$1.5M 0.16% 138
2019
Q2 		$4.13M Sell
56,800
-49,100
-46% -$3.86M 0.25% 86
2019
Q1 		$8.54M Sell
105,900
-34,700
-25% -$2.84M 0.57% 26
2018
Q4 		$13M Buy
140,600
+91,600
+187% +$8.06M 1.02% 17
2018
Q3 		$4.63M Buy
+49,000
New +$4.65M 0.4% 34

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Centiva Capital's ABBV Position: Q1 2026 in Review

Centiva Capital sold out of AbbVie (ABBV) in Q1 2026, closing a stake of 4,350 shares — an estimated $994K sold.

Centiva Capital first reported a position in ABBV in Q3 2018 and held it in 21 quarters. The position peaked at $5.93M in Q2 2020. 4,079 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Centiva Capital reported no remaining AbbVie position as of Q1 2026 after selling out during the quarter.
  • Centiva Capital sold 4,350 AbbVie shares in Q1 2026, an estimated $994K.
  • Centiva Capital first reported a position in AbbVie in Q3 2018 and held it in 21 quarters.
  • Centiva Capital's AbbVie position peaked at $5.93M in Q2 2020.
  • 4,079 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Centiva Capital's 13F filing for Q1 2026, filed 14 May 2026.